Company / R&D Expense
ArriVent BioPharma, Inc. R&D Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$79.0M
FY2024
5-year range
$64.9M / $79.0M
FY2023-FY2024
Trend
+21.8%
vs FY2023
Sector context
#158 of 210
Health Care
What the data says
ArriVent BioPharma, Inc.'s r&d expense of $79M is lower than 75% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$79M in FY2024.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 210This company $79.0M Sector average $644.1M
▼
-87.7% below sector average
Key checks
Key Insights
- In FY2024, r&d expense increased 21.8% year-over-year.
- Ranks #158 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $79.0M | +21.8% |
| FY2023 | $64.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026